J. Safra Sarasin Holding AG Trims Gilead Sciences Stake

The Swiss investment firm reduced its position in the biopharmaceutical company by 8.7% in the fourth quarter.

Mar. 31, 2026 at 9:39am

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up photograph of the inner workings of an industrial machine, with gears, levers, and other mechanical components in muted tones, conceptually representing the complex financial infrastructure and institutional investment mechanisms behind a major biopharmaceutical company.An institutional investor's reduction in holdings of a major pharmaceutical stock reflects the complex financial machinery underlying the biopharmaceutical industry.Foster City Today

J. Safra Sarasin Holding AG, a Swiss investment firm, reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.7% in the fourth quarter of 2025. The firm owned 819,403 shares of the biopharmaceutical company's stock, valued at approximately $100,574,000, making it the 11th largest position in its portfolio.

Why it matters

Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. Changes in institutional ownership of the company's stock can provide insights into market sentiment and potential shifts in the industry.

The details

According to the filing, J. Safra Sarasin Holding AG sold 78,390 shares of Gilead Sciences during the fourth quarter, reducing its position in the company. The firm now owns approximately 0.07% of Gilead Sciences' outstanding shares.

  • The filing was made on March 31, 2026, reporting on the firm's holdings as of the end of the fourth quarter of 2025.

The players

J. Safra Sarasin Holding AG

A Swiss investment firm that manages assets for high-net-worth individuals, families, and institutions.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly in antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in J. Safra Sarasin Holding AG's position in Gilead Sciences may signal a shift in investor sentiment towards the biopharmaceutical company, though the overall reasons behind the move are not entirely clear from the limited information provided. Analysts and investors will likely continue to monitor Gilead's performance and institutional ownership changes as the company navigates the competitive pharmaceutical landscape.